The estimated Net Worth of Paul A Friedman is at least $88.5 Milione dollars as of 8 April 2024. Paul Friedman owns over 26,270 units of Madrigal Pharmaceuticals Inc stock worth over $49,397,165 and over the last 21 years he sold MDGL stock worth over $33,054,261. In addition, he makes $6,093,190 as Chairman of the Board e Chief Executive Officer at Madrigal Pharmaceuticals Inc.
Sign up
Paul Friedman MDGL stock SEC Form 4 insiders trading
Paul has made over 34 trades of the Madrigal Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 26,270 units of MDGL stock worth $248,252 on 8 April 2024.
The largest trade he's ever made was exercising 771,182 units of Madrigal Pharmaceuticals Inc stock on 14 February 2014 worth over $5,899,542. On average, Paul trades about 36,351 units every 89 days since 2004. As of 8 April 2024 he still owns at least 212,005 units of Madrigal Pharmaceuticals Inc stock.
You can see the complete history of Paul Friedman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Paul Friedman biography
Dr. Paul A. Friedman M.D. serves as Chairman of the Board, Chief Executive Officer of the Company. Dr. Friedman served as the Chief Executive Officer of Incyte Corporation, a publicly-held biopharmaceutical company, or Incyte, from November 2001 until his retirement in January 2014 and has continuously served on the Incyte board since November 2001. Dr. Friedman also serves on the Board at Alexion Pharmaceuticals, a public company. Dr. Friedman served from 1994 to 1998, as President of Research & Development for the DuPont-Merck Pharmaceutical Company and from 1998 to 2001 as President of DuPont Pharmaceuticals Research Laboratories, a wholly-owned subsidiary of the DuPont Company. From 1991 to 1994, he served as Senior Vice President at Merck Research Laboratories. Prior to his tenures at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomat of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. He previously served on the board of directors of the following publicly-held pharmaceutical companies in the last five years: Cerulean Pharma Inc. (now Daré Bioscience, Inc.) (through January of 2017); Synta Pharmaceuticals Corp. (through April of 2016); and Verastem, Inc. (through April of 2017). Dr. Friedman received his A.B. in Biology from Princeton University and his M.D. from Harvard Medical School. Dr. Friedman and Dr. Taub, our Chief Medical Officer, President, Research & Development, and a director, are married.
What is the salary of Paul Friedman?
As the Chairman of the Board e Chief Executive Officer of Madrigal Pharmaceuticals Inc, the total compensation of Paul Friedman at Madrigal Pharmaceuticals Inc is $6,093,190. There are no executives at Madrigal Pharmaceuticals Inc getting paid more.
What's Paul Friedman's mailing address?
Paul's mailing address filed with the SEC is C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, 19428.
Insiders trading at Madrigal Pharmaceuticals Inc
Over the last 8 years, insiders at Madrigal Pharmaceuticals Inc have traded over $471,222,585 worth of Madrigal Pharmaceuticals Inc stock and bought 443,785 units worth $79,114,183 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Paul A Friedman e Bros. Advisors Lp667, L.P.B.... On average, Madrigal Pharmaceuticals Inc executives and independent directors trade stock every 56 days with the average trade being worth of $20,602,093. The most recent stock trade was executed by William John Sibold on 9 September 2024, trading 6,363 units of MDGL stock currently worth $1,551,490.
What does Madrigal Pharmaceuticals Inc do?
madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
What does Madrigal Pharmaceuticals Inc's logo look like?
Complete history of Paul Friedman stock trades at Alexion Pharmaceuticals, Incyte, Madrigal Pharmaceuticals Inc, Verastem Inc e Prelude Therapeutics Inc
Madrigal Pharmaceuticals Inc executives and stock owners
Madrigal Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Paul Friedman,
Chairman of the Board, Chief Executive Officer -
Rebecca Taub,
President of Research and Development, Chief Medical Officer, Director -
Brian Lynch,
Senior Vice President, General Counsel -
Marc Schneebaum,
Chief Financial Officer, Senior Vice President -
James Daly,
Independent Director -
Dr. Paul A. Friedman M.D.,
Chairman & CEO -
Dr. Rebecca A. Taub M.D.,
Founder, Chief Medical Officer, Pres of R&D and Director -
Remy Sukhija,
Sr. VP & Chief Commercial Officer -
Brian J. Lynch J.D.,
Sr. VP & Gen. Counsel -
Brian J. Lynch,
Sr. VP & Gen. Counsel -
Kenneth Bate,
Independent Director -
Richard Levy,
Independent Director -
Keith Gollust,
Independent Director -
David Milligan,
Independent Director -
Frederick Craves,
Lead Independent Director -
Remy Sukhija,
Senior Vice President, Chief Commercial Officer -
Edward Chiang,
Sr. VP of Clinical & Technical Operations -
Dr. Stephen Dodge M.B.A., Pharm.D.,
Sr. VP & Global Head of Medical Affairs -
Dr. Robert E. Waltermire Ph.D.,
Chief Pharmaceutical Devel. Officer -
Thomas W. Hare,
Sr. VP of Clinical Management -
Dr. Kianoush Motesharei Ph.d.,
Sr. VP of Bus. & Corp. Devel. -
Alex G. Howarth,
Chief Financial Officer -
Bros. Advisors Lp667, L.P.B...,
-
Bros. Advisors Lp667, L.P.B...,
-
Chen Schor,
Former President and CEO -
Wendy E Rieder,
Former SVP, Gen. Counsel -
City Capital Llc Bay,
Director -
City Capital Llc Bay City C...,
-
Alex G. Howarth,
Chief Financial Officer -
Robert E. Waltermire,
Senior VP, Chief Pharma Dev. -
Bros. Advisors Lp Baker,
-
Shannon T Kelley,
General Counsel -
William John Sibold,
President and CEO -
Carole Huntsman,
Chief Commercial Officer -
Fred B Craves,